Skip to content

Pharmacotherapeutic and physicochemical evaluation of Ayabirungarajakarpam – A Siddha drug for Paandu - Anaemia

Pharmacotherapeutic and physicochemical evaluation of Ayabirungarajakarpam – A poly herbometallic drug for Paandu –Anaemia

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2018/035
Enrollment
216
Registered
2018-10-29
Start date
2018-11-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaemia

Interventions

The study will be done at the Outpatient Department (OPD) of Teaching Hospital of Siddhamedicine,Trincomalee This is a single arm, non randomized study and patients with classical clinical features o

Sponsors

Dr. V. Elango
Lead Sponsor
Dr.V. Shiyamala
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Age – 19 -60 years Male and female With the following cardinal signs of iron deficiency anaemia 1. Pallor 2. Palpitation 3. Extreame fatigue 4. Exertional dyspnoea With a hemoglobin value of 7 – 11g/dL With a serum ferritin level of<12 micrograms/L

Exclusion criteria

Exclusion criteria: Patients with - Haemoglobin below7g/dL - Serum ferritin below 8 micrograms/L - Diagnosed with any other type of anaemia other than Iron deficiency anaemia. Patients with the following complications -Cardiac diseases -Renal diseases -Liver diseases -Diabetes mellitus -Hypertension -Thalassaemia minor -Bleeding disorders -Haemoglopinapathies -Defective absorption E.g. Patients with gastrectomy and gastrojejunostomy. Pregnancy Lactating mothers

Design outcomes

Primary

MeasureTime frame
The increase in haemoglobin g/dL and the serum ferritin micrograms/L per month as determined by Cyanomethoglobin method and ELISA kit respectively [15th, 30th , 48th, 62nd ,76th ,90th day from initiating therapy.]

Secondary

MeasureTime frame
Physical signs and symptoms as follows, determined by physical examination and interview of patients by investigators. *Pallor *Palpitation *Effort intolerance *Fatigue *Breathlessness These signs and symptoms will be measured using a graded point scale of 0-5 [15th, 30th, 48th, 62nd ,76th ,90th day from initiating therapy]

Countries

Sri Lanka

Contacts

Public ContactDr.N.Varnakulendran

Senior lecturer

drvarnan@gmail.comTel: 0262227812

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026